We performed a randomized controlled trial in 30 HIV-infected individuals to either continue tenofovir/emtricitabine/efavirenz (Continuation Group) or change to tenofovir/emtricitabine/raltegravir (Change Group) for 24 weeks. the usage of potent antiretroviral therapies (Artwork) coronary disease (CVD) provides emerged as a respected reason behind morbidity and mortality.1 One mechanism where HIV infection or its therapies can lead… Continue reading We performed a randomized controlled trial in 30 HIV-infected individuals to